SEC Form 4 · accession 0000899243-16-029446
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John G. Aunins
Officer — Chief Technology Officer & EVP
Period of report
Sep 19, 2016
Accepted (ET)
Sep 20, 2016 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.55 | Sep 19, 2016 | A | 30,000 | A | — | Sep 18, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on September 19, 2017. The remainder of the shares will vest in 12 equal quarterly installments thereafter.